William Lis
Director/Board Member at ZAI LAB LIMITED
Net worth: 701 976 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ya jing Chen | M | 56 | 3 years | |
| Susan S. Prohaska | M | - |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | 6 years |
| Ying Du | M | 59 | 10 years | |
| Scott Morrison | M | 66 | 3 years | |
| Lina Zhang | F | - | - | |
| F. Edmondson | M | 58 | 4 years | |
| Judith Shizuru | M | 68 |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | - |
| Peter Wirth | M | 73 | 7 years | |
| Michel Vounatsos | M | 62 | 1 years | |
| John Diekman | M | 81 | 7 years | |
| Richard Gaynor | M | 74 | 3 years | |
| Kai Xian Chen | M | 78 | 6 years | |
| Joshua Smiley | M | 54 | 2 years | |
| Wing Yu Leung | F | 53 | 10 years | |
| Lonnie Moulder | M | 66 | 5 years | |
| Jonathan A. Barr | M | - | 3 years | |
| James Yan | M | 60 | 4 years | |
| Jonathan Wang | M | 42 | 10 years | |
| Harald Reinhart | M | 72 | 7 years | |
| Anna Phil | M | 36 |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | 5 years |
| Kurt von Emster | M | 56 |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA. | 5 years |
| Li Ni Ou Yang | F | - | 2 years | |
| Ann Beasley | F | - | 4 years | |
| Peter Huang | M | - | 2 years | |
| Ning Xu | M | 59 | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tao Fu | M | 52 |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 12 years |
| James Topper | M | 62 | 2 years | |
| Rafael Amado | M | 60 | - | |
| Robert M. Califf | M | 72 | 3 years | |
| Eric Aguiar | M | 62 | 2 years | |
| Michael M. Kitt | M | 73 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 12 years |
| Laura Brege | F | 66 | 5 years | |
| W. Richey Neuman | M | - | 3 years | |
| Suzanne Hooper | F | 58 | 1 years | |
| Raj Shah | M | 46 | 2 years | |
| Jean George | F | 66 | 8 years | |
| Christine Siu | F | 47 | 3 years | |
| Nicholas G. Galakatos | M | 66 | 12 years | |
| Jan Egbert de Vries | M | 80 |
Tr1x, Inc.
 Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | - |
| Uma Sinha | M | 67 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 22 years |
| John Curnutte | M | 72 | 8 years | |
| Mark W. Gossett | M | - | - | |
| John Moriarty | M | 56 | 2 years | |
| Ali Satvat | M | 46 | 3 years | |
| Todd J. Lorenz | M | 70 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 years |
| Russell C. Hirsch | M | 62 | 10 years | |
| Jean-Jacques Bienaimé | M | 70 | 4 years | |
| Peggy Phillips | F | 70 | 7 years | |
| John Johnson | M | 66 | - | |
| John J. Schembri | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
| Charles Homcy | M | 75 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 14 years |
| David Stump | M | 74 | - | |
| Dennis Fenton | M | 72 | - | |
| Hollings Renton | M | 77 | 10 years | |
| Duke Rohlen | M | 56 | 1 years | |
| Michael Berry | M | 59 | 2 years | |
| Ron Aldridge | M | - | - | |
| Lina Zhang | F | - | - | |
| Jeet Mahal | M | 52 | 11 years | |
| John B. Russell | M | 51 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 2 years |
| Alexander M. Gold | M | - | 4 years | |
| Danielle Olander | F | - | 9 years | |
| Stacy Markel | F | 59 | 3 years | |
| Valeria Fantin | M | - | 1 years | |
| Yong Jiang Hei | M | 61 | 3 years | |
| Angela Jiang | F | - | - | |
| Karl Hsu | M | - | - | |
| Ki Chul Cho | M | 46 | 5 years | |
| Mike Ouimette | M | 51 | 6 years | |
| Kala Subramanian | M | 57 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Ahmad Sadr | M | - | 1 years | |
| Ernie Meyer | M | 60 | - | |
| Yi Liang | M | 53 | 6 years | |
| R. Ramelmeier | M | 62 | 3 years | |
| Patrick A. Broderick | M | 66 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 3 years |
| Walter H. Bee | M | - |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 4 years |
| Robert E. Mackey | M | - | - | |
| Farah Champsi | F | 62 | 8 years | |
| Randall Kaye | M | 61 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 2 years |
| Andrew A. Protter | M | 70 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 24 years |
| Santosh Vetticaden | M | 65 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 4 years |
| Sarvajit Chakravarty | M | 58 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 14 years |
| Daron Evans | M | 50 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 2 years |
| Peter M. Strumph | M | 59 | - | |
| Mark D. Perrin | M | 67 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 years |
| Richard B. Brewer | M | 72 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 6 years |
| George F. Schreiner | M | 74 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 9 years |
| Matthew R. Hooper | M | 66 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 6 years |
| Russell Cox | M | 60 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 4 years |
| F. Allan Gordon | M | - |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 3 years |
| George T. Jue | M | 71 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 5 years |
| Ho Young Huh | M | 54 | - | |
| Glenn Brame | M | 67 | - | |
| Dennis O. Driver | M | - |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 6 years |
| Glenn Michelson | M | 59 | 1 years | |
| Daniel D. Gretler | M | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 years |
| Debanjan Ray | M | 46 | 2 years | |
| Anjali Pandey | M | - | 15 years | |
| Alan Sandler | M | 67 | 2 years | |
| David Parry | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 70 | 70.00% |
| Cayman Islands | 31 | 31.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William Lis
- Personal Network
